clorazepate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
diazepam derivatives 711 57109-90-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • clorazepate monopotassium
  • clorazepate potassium
  • clorazepic acid
  • clorazepate
  • chlorazepate
  • clorazepate dipotassium
  • dipotassium clorazepate
  • potassium clorazepate
A water-soluble benzodiazepine derivative effective in the treatment of anxiety. It has also muscle relaxant and anticonvulsant actions.
  • Molecular weight: 314.73
  • Formula: C16H11ClN2O3
  • CLOGP: 2.51
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 2
  • TPSA: 78.76
  • ALOGS: -4.10
  • ROTB: 2
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
20 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0.50 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 5.45 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 91 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.20 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 1.10 mL/min/kg Lombardo F, Berellini G, Obach RS
t_half (Half-life) 2.40 hours Lombardo F, Berellini G, Obach RS
S (Water solubility) 100 mg/mL Bocci G, Oprea TI, Benet LZ

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 -0.333 Moderate 0.73
caco2-efflux Caco-2 efflux ratio (BA/AB) 6.138 Moderate 0.73
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 4.130 10^-6 cm/s Moderate 0.73
dh-clint Dog hepatocyte intrinsic clearance 2.432 uL/min/10^6 cells Moderate 0.73
dppb Dog plasma protein binding (% unbound) 2.850 % Moderate 0.73
fcs-ppb Fetal calf serum protein binding (% unbound) 5.280 % Moderate 0.73
herg hERG pIC50 4.668 pIC50 Moderate 0.73
hh-clint Human hepatocyte intrinsic clearance 1.368 uL/min/10^6 cells Moderate 0.73
hlm-clint Human liver microsomal intrinsic clearance 3.304 uL/min/mg protein Moderate 0.73
hppb Human plasma protein binding (% unbound) 2.820 % Moderate 0.73
kinase-safety-class ACVR2B,AURKA,AXL,BRAF,BTK,CAMK2D,CDK5,CDK9,DYRK1B,EIF2AK3,ERBB2,GRK2,ITK,MAPK7,PDK1,PDK2,PDK4,PIK3CB,PRKDC,TEK 20
kinase-selectivity-class ACVR2B,AXL,EIF2AK3,GRK2,MAP2K6,MAPK7,TTK 7
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 1.387 Moderate 0.73
mh-clint Mouse hepatocyte intrinsic clearance 2.495 Moderate 0.73
mppb Mouse plasma protein binding (% unbound) 9.820 Moderate 0.73
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 0.425 Moderate 0.73
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 3.460 % Moderate 0.73
rh-clint Rat hepatocyte intrinsic clearance 1.854 uL/min/10^6 cells Moderate 0.73
rh-fuinc Rat hepatocyte fraction unbound in incubation 82.820 % Moderate 0.73
rppb Rat plasma protein binding (% unbound) 2.510 % Moderate 0.73
solubility-dd Solubility at pH 7.4 in DMSO 916.220 uM Moderate 0.73

Approvals:

DateAgencyCompanyOrphan
June 23, 1972 FDA RECORDATI RARE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Coma 274.76 22.30 133 8054 72499 90547761
Suicide attempt 126.70 22.30 81 8106 75318 90544942
Coma blister 118.33 22.30 19 8168 134 90620126
Poisoning deliberate 113.41 22.30 46 8141 16440 90603820
Drug abuse 113.04 22.30 78 8109 82269 90537991
Somnolence 108.58 22.30 113 8074 208971 90411289
Depressed level of consciousness 95.33 22.30 67 8120 72717 90547543
Toxicity to various agents 94.72 22.30 123 8064 287723 90332537
Intentional overdose 84.38 22.30 69 8118 93765 90526495
Drug interaction 77.02 22.30 109 8078 276344 90343916
Erythrodermic psoriasis 75.61 22.30 18 8169 1088 90619172
Seizure 74.72 22.30 80 8107 152549 90467711
Metabolic acidosis 69.99 22.30 50 8137 55626 90564634
Neurological decompensation 67.45 22.30 21 8166 3480 90616780
Rhabdomyolysis 66.66 22.30 47 8140 51209 90569051
Disorientation 65.76 22.30 44 8143 44070 90576190
Dermatitis exfoliative 65.59 22.30 23 8164 5513 90614747
Loss of consciousness 62.53 22.30 70 8117 140168 90480092
Fall 61.85 22.30 135 8052 481675 90138585
Antithrombin III 61.53 22.30 11 8176 156 90620104
Shock 61.28 22.30 36 8151 28742 90591518
Pancreatic failure 60.58 22.30 16 8171 1476 90618784
Basal ganglion degeneration 58.26 22.30 12 8175 370 90619890
Behaviour disorder 57.77 22.30 20 8167 4615 90615645
Hyperthyroidism 55.76 22.30 29 8158 18281 90601979
Stupor 54.49 22.30 20 8167 5462 90614798
Hyperventilation 54.03 22.30 21 8166 6707 90613553
Tissue infiltration 53.50 22.30 13 8174 857 90619403
Toxic epidermal necrolysis 52.25 22.30 34 8153 32494 90587766
Electrolyte imbalance 51.33 22.30 30 8157 23715 90596545
Overdose 51.14 22.30 67 8120 157642 90462618
Euphoric mood 51.06 22.30 19 8168 5390 90614870
Anaesthesia 50.32 22.30 11 8176 453 90619807
Monoplegia 50.26 22.30 17 8170 3657 90616603
Acute hepatic failure 50.09 22.30 29 8158 22532 90597728
Cholecystitis 49.07 22.30 26 8161 17014 90603246
Multiple organ dysfunction syndrome 48.68 22.30 44 8143 68292 90551968
Uterine enlargement 47.85 22.30 13 8174 1335 90618925
Urinary retention 43.11 22.30 32 8155 37712 90582548
Psychogenic seizure 42.68 22.30 13 8174 2003 90618257
Hepatic perfusion disorder 42.18 22.30 7 8180 62 90620198
Inguinal hernia 42.17 22.30 13 8174 2085 90618175
Mydriasis 40.68 22.30 22 8165 14990 90605270
Psychomotor hyperactivity 38.17 22.30 20 8167 12793 90607467
Sudden cardiac death 37.25 22.30 12 8175 2220 90618040
Delusion 36.72 22.30 20 8167 13820 90606440
Drug monitoring procedure incorrectly performed 36.46 22.30 8 8179 335 90619925
Drug dependence 36.06 22.30 26 8161 29301 90590959
Traumatic haematoma 35.56 22.30 11 8176 1784 90618476
Neutrophil toxic granulation present 35.51 22.30 7 8180 172 90620088
Renal failure 35.43 22.30 51 8136 130956 90489304
Catatonia 35.23 22.30 15 8172 6041 90614219
Hypotension 34.84 22.30 85 8102 325312 90294948
Altered state of consciousness 34.38 22.30 26 8161 31506 90588754
Regressive behaviour 34.14 22.30 7 8180 211 90620049
Intra-abdominal haematoma 33.64 22.30 11 8176 2133 90618127
Hypochromic anaemia 33.50 22.30 11 8176 2160 90618100
Intervertebral disc disorder 33.35 22.30 14 8173 5446 90614814
Granulomatous liver disease 32.98 22.30 9 8178 940 90619320
Anterograde amnesia 31.90 22.30 8 8179 601 90619659
Dysaesthesia 30.51 22.30 13 8174 5242 90615018
Hypersensitivity 30.31 22.30 3 8184 454674 90165586
Neuroleptic malignant syndrome 29.82 22.30 18 8169 15078 90605182
Hyponatraemia 29.06 22.30 47 8140 133491 90486769
Miosis 28.81 22.30 15 8172 9469 90610791
Social avoidant behaviour 28.64 22.30 11 8176 3402 90616858
Derailment 28.52 22.30 5 8182 63 90620197
Serotonin syndrome 28.16 22.30 25 8162 37862 90582398
Suicidal ideation 28.09 22.30 34 8153 73821 90546439
Drug withdrawal syndrome 27.64 22.30 22 8165 28701 90591559
Disturbance in attention 27.17 22.30 27 8160 47082 90573178
Somatic delusion 26.92 22.30 7 8180 607 90619653
Respiratory disorder 26.56 22.30 31 8156 64785 90555475
Abdominal tenderness 26.20 22.30 14 8173 9310 90610950
Conversion disorder 25.74 22.30 9 8178 2137 90618123
Eosinophilia 25.65 22.30 21 8166 28512 90591748
Tremor 25.61 22.30 48 8139 153125 90467135
Intestinal villi atrophy 25.34 22.30 6 8181 354 90619906
Rash 25.23 22.30 21 8166 796079 89824181
Hyperpyrexia 25.10 22.30 11 8176 4750 90615510
Livedo reticularis 24.98 22.30 10 8177 3449 90616811
Hypokinetic dysarthria 24.93 22.30 4 8183 28 90620232
Klebsiella infection 24.90 22.30 14 8173 10283 90609977
Hyperammonaemia 24.85 22.30 12 8175 6463 90613797
Neonatal aspiration 24.70 22.30 5 8182 141 90620119
Mucosal pain 24.58 22.30 4 8183 31 90620229
Agranulocytosis 23.86 22.30 22 8165 34980 90585280
Withdrawal syndrome 23.29 22.30 18 8169 22506 90597754
Arthropathy 22.94 22.30 3 8184 366239 90254021
Colitis ischaemic 22.55 22.30 14 8173 12332 90607928

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Coma 214.61 22.02 107 4385 53447 42563396
Somnolence 87.54 22.02 90 4402 141015 42475828
Wrong patient received product 80.26 22.02 25 4467 3558 42613285
Hepatitis acute 78.22 22.02 31 4461 8944 42607899
Intentional overdose 75.80 22.02 54 4438 51402 42565441
Wrong patient 66.18 22.02 15 4477 624 42616219
Slow speech 64.27 22.02 18 4474 1772 42615071
Anticoagulation drug level above therapeutic 49.44 22.02 16 4476 2574 42614269
Stevens-Johnson syndrome 43.94 22.02 28 4464 22150 42594693
Toxic epidermal necrolysis 41.49 22.02 29 4463 26721 42590122
Tachycardia 41.28 22.02 52 4440 101035 42515808
Drug interaction 37.47 22.02 85 4407 266914 42349929
Asphyxia 37.29 22.02 18 4474 8308 42608535
Miosis 37.07 22.02 21 4471 13425 42603418
Drug abuse 36.73 22.02 50 4442 104721 42512122
Cor pulmonale acute 36.33 22.02 8 4484 291 42616552
Acute respiratory distress syndrome 34.05 22.02 27 4465 30081 42586762
Prothrombin level decreased 33.96 22.02 10 4482 1176 42615667
Suicide attempt 33.26 22.02 32 4460 46068 42570775
Restlessness 32.58 22.02 26 4466 29223 42587620
Aggression 32.51 22.02 31 4461 44132 42572711
Faecal vomiting 29.66 22.02 8 4484 684 42616159
Blister 27.59 22.02 23 4469 27467 42589376
Mucosal erosion 26.71 22.02 8 4484 997 42615846
Pneumonia aspiration 25.75 22.02 29 4463 50049 42566794
Sudden death 25.71 22.02 18 4474 16611 42600232
Psychomotor skills impaired 25.59 22.02 12 4480 5192 42611651
Drug use disorder 25.45 22.02 15 4477 10318 42606525
Toxicity to various agents 24.70 22.02 66 4426 229070 42387773
Toxic skin eruption 23.92 22.02 16 4476 13714 42603129
Clonus 23.32 22.02 10 4482 3510 42613333
Poisoning deliberate 23.11 22.02 14 4478 10120 42606723
Tobacco poisoning 23.05 22.02 4 4488 40 42616803
Lipase increased 22.57 22.02 14 4478 10552 42606291

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Coma 483.56 20.66 241 11657 117628 110459773
Somnolence 196.02 20.66 198 11700 297251 110280150
Intentional overdose 156.83 20.66 123 11775 132378 110445023
Suicide attempt 146.73 20.66 107 11791 103287 110474114
Poisoning deliberate 129.22 20.66 61 11837 26270 110551131
Drug abuse 112.81 20.66 116 11782 177295 110400106
Coma blister 107.10 20.66 19 11879 213 110577188
Toxicity to various agents 105.89 20.66 187 11711 480368 110097033
Depressed level of consciousness 105.10 20.66 91 11807 112187 110465214
Drug interaction 95.51 20.66 183 11715 500000 110077401
Toxic epidermal necrolysis 85.66 20.66 61 11837 56666 110520735
Wrong patient received product 79.01 20.66 29 11869 6645 110570756
Hepatitis acute 66.91 20.66 35 11863 18731 110558670
Metabolic acidosis 64.75 20.66 66 11832 99678 110477723
Rhabdomyolysis 64.60 20.66 72 11826 120329 110457072
Miosis 64.43 20.66 36 11862 21947 110555454
Shock 63.86 20.66 50 11848 53538 110523863
Overdose 62.03 20.66 99 11799 233695 110343706
Erythrodermic psoriasis 61.82 20.66 18 11880 1992 110575409
Neurological decompensation 60.25 20.66 24 11874 6859 110570542
Disorientation 57.60 20.66 53 11845 70618 110506783
Basal ganglion degeneration 54.59 20.66 12 11886 424 110576977
Urinary retention 52.45 20.66 50 11848 69633 110507768
Slow speech 52.26 20.66 18 11880 3430 110573971
Dermatitis exfoliative 51.73 20.66 25 11873 11322 110566079
Seizure 51.06 20.66 88 11810 221097 110356304
Pancreatic failure 50.60 20.66 16 11882 2338 110575063
Uterine enlargement 49.64 20.66 13 11885 972 110576429
Stupor 49.49 20.66 22 11876 8243 110569158
Tissue infiltration 48.90 20.66 13 11885 1030 110576371
Anaesthesia 45.52 20.66 11 11887 593 110576808
Hyperventilation 44.72 20.66 21 11877 8926 110568475
Wrong patient 44.23 20.66 13 11885 1486 110575915
Faecal vomiting 43.67 20.66 13 11885 1553 110575848
Behaviour disorder 43.21 20.66 21 11877 9626 110567775
Hypotension 43.13 20.66 139 11759 523710 110053691
Psychomotor skills impaired 42.95 20.66 19 11879 7039 110570362
Monoplegia 42.56 20.66 17 11881 4892 110572509
Eosinophilia 42.52 20.66 41 11857 57895 110519506
Euphoric mood 41.91 20.66 20 11878 8807 110568594
Drug dependence 41.70 20.66 38 11860 49982 110527419
Hepatic perfusion disorder 40.85 20.66 7 11891 63 110577338
Hyperthyroidism 40.81 20.66 30 11868 29231 110548170
Pneumonia aspiration 39.19 20.66 46 11852 81187 110496214
Altered state of consciousness 38.97 20.66 39 11859 57587 110519814
Psychogenic seizure 38.40 20.66 13 11885 2351 110575050
Aggression 38.08 20.66 39 11859 59171 110518230
Fall 36.70 20.66 145 11753 603337 109974064
Anticoagulation drug level above therapeutic 36.58 20.66 15 11883 4615 110572786
Tachycardia 36.04 20.66 77 11821 226568 110350833
Loss of consciousness 35.10 20.66 70 11828 196236 110381165
Sudden death 33.99 20.66 25 11873 24370 110553031
Mydriasis 33.83 20.66 24 11874 22133 110555268
Sudden cardiac death 33.74 20.66 15 11883 5622 110571779
Prothrombin level decreased 33.57 20.66 11 11887 1799 110575602
Psychomotor hyperactivity 33.38 20.66 23 11875 20254 110557147
Disturbance in attention 33.10 20.66 37 11861 61958 110515443
Acute hepatic failure 32.96 20.66 29 11869 36439 110540962
Regressive behaviour 32.70 20.66 7 11891 218 110577183
Electrolyte imbalance 32.58 20.66 29 11869 36999 110540402
Antithrombin III 32.39 20.66 6 11892 87 110577314
Wrong product administered 32.25 20.66 18 11880 10942 110566459
Neutrophil toxic granulation present 32.02 20.66 7 11891 241 110577160
Colitis ischaemic 31.27 20.66 21 11877 17729 110559672
Intervertebral disc disorder 30.86 20.66 14 11884 5498 110571903
Cholecystitis 30.50 20.66 24 11874 25858 110551543
Traumatic haematoma 30.44 20.66 11 11887 2410 110574991
Delusion 30.11 20.66 23 11875 23732 110553669
Drug withdrawal syndrome 29.95 20.66 28 11870 38026 110539375
Renal failure 29.37 20.66 71 11827 226503 110350898
Hyponatraemia 29.07 20.66 69 11829 217584 110359817
Cor pulmonale acute 28.75 20.66 8 11890 752 110576649
Haemodynamic instability 28.66 20.66 22 11876 22866 110554535
Neuroleptic malignant syndrome 28.63 20.66 26 11872 34033 110543368
Drug monitoring procedure incorrectly performed 28.52 20.66 8 11890 775 110576626
Irritability 28.07 20.66 30 11868 47779 110529622
Sedation 28.02 20.66 36 11862 69647 110507754
Asphyxia 27.92 20.66 18 11880 14197 110563204
Anterograde amnesia 27.52 20.66 8 11890 880 110576521
Hypochromic anaemia 27.45 20.66 11 11887 3190 110574211
Restlessness 27.37 20.66 32 11866 56227 110521174
Stevens-Johnson syndrome 26.78 20.66 29 11869 46872 110530529
Derailment 26.59 20.66 5 11893 79 110577322
Intra-abdominal haematoma 26.59 20.66 11 11887 3461 110573940
Catatonia 26.46 20.66 16 11882 11284 110566117
Drug use disorder 26.27 20.66 19 11879 18055 110559346
Serotonin syndrome 26.07 20.66 32 11866 59121 110518280
Hypersensitivity 25.64 20.66 6 11892 403992 110173409
Pancreatitis acute 25.59 20.66 32 11866 60242 110517159
Acute kidney injury 25.41 20.66 135 11763 635295 109942106
Dysaesthesia 25.06 20.66 13 11885 6834 110570567
Social avoidant behaviour 24.99 20.66 12 11886 5357 110572044
Lymphocytosis 24.90 20.66 12 11886 5399 110572002
Livedo reticularis 24.70 20.66 12 11886 5494 110571907
Salivary hypersecretion 24.60 20.66 18 11880 17403 110559998
Somatic delusion 24.60 20.66 7 11891 714 110576687
Withdrawal syndrome 24.52 20.66 23 11875 31357 110546044
Confusional state 24.06 20.66 107 11791 468573 110108828
Suicidal ideation 23.81 20.66 39 11859 93898 110483503
Inguinal hernia 23.59 20.66 13 11885 7712 110569689
Hypokinetic dysarthria 23.55 20.66 4 11894 34 110577367
Multiple organ dysfunction syndrome 23.48 20.66 51 11847 151659 110425742
Electrocardiogram QT prolonged 23.36 20.66 42 11856 108918 110468483
Conversion disorder 23.33 20.66 9 11889 2361 110575040
Pain 23.33 20.66 42 11856 954913 109622488
Rash maculo-papular 23.27 20.66 34 11864 74188 110503213
Granulomatous liver disease 22.97 20.66 8 11890 1576 110575825
Sinusitis 21.86 20.66 3 11895 296685 110280716
Mucosal pain 21.86 20.66 4 11894 54 110577347
Cardio-respiratory arrest 21.53 20.66 42 11856 115794 110461607
Intestinal villi atrophy 21.49 20.66 6 11892 571 110576830
Respiratory disorder 21.37 20.66 32 11866 71350 110506051
Arthralgia 21.16 20.66 32 11866 779600 109797801
Nasopharyngitis 21.13 20.66 8 11890 394353 110183048
Swelling 20.77 20.66 6 11892 351035 110226366

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N05BA05 NERVOUS SYSTEM
PSYCHOLEPTICS
ANXIOLYTICS
Benzodiazepine derivatives
FDA CS M0002356 Benzodiazepines
CHEBI has role CHEBI:35474 anxiolytic drug
CHEBI has role CHEBI:35623 anticonvulsant
CHEBI has role CHEBI:50266 prodrug
CHEBI has role CHEBI:50268 GABA modulator
MeSH PA D000927 Anticonvulsants
MeSH PA D002492 Central Nervous System Depressants
MeSH PA D011619 Psychotropic Drugs
MeSH PA D014151 Anti-Anxiety Agents
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018682 GABA Agents
MeSH PA D018757 GABA Modulators
FDA EPC N0000175694 Benzodiazepine

Related Drugs by ATC class:

N05BA Benzodiazepine derivatives 23 drugs
adinazolamalprazolambentazepambromazepamcamazepamchlordiazepoxideclobazamclotiazepamcloxazolamdiazepamethyl loflazepateetizolam show all 23 →

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Anxiety indication 48694002
Alcohol withdrawal syndrome indication 191480000
Partial Epilepsy Treatment Adjunct indication
Suicidal thoughts contraindication 6471006
Alcohol intoxication contraindication 25702006
Depressive disorder contraindication 35489007
Substance abuse contraindication 66214007
Psychotic disorder contraindication 69322001
Sleep apnea contraindication 73430006 DOID:0050847
Kidney disease contraindication 90708001 DOID:557
Hypoalbuminemia contraindication 119247004
Disease of liver contraindication 235856003 DOID:409
Anemia contraindication 271737000 DOID:2355
Pregnancy, function contraindication 289908002
Severe chronic obstructive pulmonary disease contraindication 313299006
Angle-closure glaucoma contraindication 392291006 DOID:13550
Central nervous system depression contraindication 418072004




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 3.55 acidic
pKa2 13.86 acidic
pKa3 2.31 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
GABA-A receptor alpha-1/beta-2/gamma-2 Ion channel POSITIVE ALLOSTERIC MODULATOR EC50 7.47 WOMBAT-PK CHEMBL
GABA-A receptor alpha-2/beta-3/gamma-2 Ion channel POSITIVE ALLOSTERIC MODULATOR WOMBAT-PK CHEMBL
GABA-A receptor alpha-3/beta-3/gamma-2 Ion channel POSITIVE ALLOSTERIC MODULATOR WOMBAT-PK CHEMBL
GABA-A receptor alpha-5/beta-3/gamma-2 Ion channel POSITIVE ALLOSTERIC MODULATOR WOMBAT-PK CHEMBL

External reference:

IDSource
D00694 KEGG_DRUG
5991-71-9 SECONDARY_CAS_RN
23887-31-2 SECONDARY_CAS_RN
2353 RXNORM
C0008174 UMLSCUI
CHEBI:3761 CHEBI
CHEMBL1213252 ChEMBL_ID
CHEMBL2106085 ChEMBL_ID
CHEMBL2096631 ChEMBL_ID
DB00628 DRUGBANK_ID
2809 PUBCHEM_CID
7548 IUPHAR_LIGAND_ID
388 MMSL
4481 MMSL
d00198 MMSL
001456 NDDF
001457 NDDF
001458 NDDF
371349001 SNOMEDCT_US
387453004 SNOMEDCT_US
39815009 SNOMEDCT_US
D003009 MESH_DESCRIPTOR_UI
MS63G8NQUI UNII
2224 INN_ID
4018712 VANDF
4019688 VANDF

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
CLORAZEPATE DIPOTASSIUM Human Prescription Drug Label 1 13107-282 TABLET 3.75 mg ORAL ANDA 26 sections
CLORAZEPATE DIPOTASSIUM Human Prescription Drug Label 1 13107-283 TABLET 7.50 mg ORAL ANDA 26 sections
CLORAZEPATE DIPOTASSIUM Human Prescription Drug Label 1 13107-284 TABLET 15 mg ORAL ANDA 26 sections
CLORAZEPATE DIPOTASSIUM Human Prescription Drug Label 1 13107-319 TABLET 3.75 mg ORAL ANDA 26 sections
CLORAZEPATE DIPOTASSIUM Human Prescription Drug Label 1 13107-320 TABLET 7.50 mg ORAL ANDA 26 sections
CLORAZEPATE DIPOTASSIUM Human Prescription Drug Label 1 13107-321 TABLET 15 mg ORAL ANDA 26 sections
Clorazepate Dipotassium HUMAN PRESCRIPTION DRUG LABEL 1 21695-433 TABLET 3.75 mg ORAL ANDA 20 sections
Clorazepate Dipotassium HUMAN PRESCRIPTION DRUG LABEL 1 21695-434 TABLET 7.50 mg ORAL ANDA 20 sections
Clorazepate Dipotassium HUMAN PRESCRIPTION DRUG LABEL 1 43063-893 TABLET 15 mg ORAL ANDA 22 sections
Clorazepate Dipotassium HUMAN PRESCRIPTION DRUG LABEL 1 51672-4042 TABLET 3.75 mg ORAL ANDA 22 sections
Clorazepate Dipotassium HUMAN PRESCRIPTION DRUG LABEL 1 51672-4043 TABLET 7.50 mg ORAL ANDA 22 sections
Clorazepate Dipotassium HUMAN PRESCRIPTION DRUG LABEL 1 51672-4044 TABLET 15 mg ORAL ANDA 22 sections
Clorazepate Dipotassium HUMAN PRESCRIPTION DRUG LABEL 1 58118-4042 TABLET 3.75 mg ORAL ANDA 22 sections
Clorazepate Dipotassium HUMAN PRESCRIPTION DRUG LABEL 1 58118-4043 TABLET 7.50 mg ORAL ANDA 22 sections
Clorazepate Dipotassium HUMAN PRESCRIPTION DRUG LABEL 1 58118-4044 TABLET 15 mg ORAL ANDA 22 sections
Clorazepate Dipotassium HUMAN PRESCRIPTION DRUG LABEL 1 60505-4754 TABLET 3.75 mg ORAL ANDA 17 sections
Clorazepate Dipotassium HUMAN PRESCRIPTION DRUG LABEL 1 60505-4755 TABLET 7.50 mg ORAL ANDA 17 sections
Clorazepate Dipotassium HUMAN PRESCRIPTION DRUG LABEL 1 60505-4756 TABLET 15 mg ORAL ANDA 17 sections
Clorazepate dipotassium HUMAN PRESCRIPTION DRUG LABEL 1 63304-552 TABLET 3.75 mg ORAL ANDA 16 sections
Clorazepate dipotassium HUMAN PRESCRIPTION DRUG LABEL 1 63304-553 TABLET 7.50 mg ORAL ANDA 16 sections
Clorazepate dipotassium HUMAN PRESCRIPTION DRUG LABEL 1 63304-554 TABLET 15 mg ORAL ANDA 16 sections
Clorazepate Dipotassium HUMAN PRESCRIPTION DRUG LABEL 1 67046-1462 TABLET 15 mg ORAL ANDA 20 sections
Clorazepate Dipotassium HUMAN PRESCRIPTION DRUG LABEL 1 67046-1501 TABLET 15 mg ORAL ANDA 21 sections
Clorazepate Dipotassium HUMAN PRESCRIPTION DRUG LABEL 1 67046-1601 TABLET 7.50 mg ORAL ANDA 21 sections
Clorazepate dipotassium HUMAN PRESCRIPTION DRUG LABEL 1 67046-904 TABLET 7.50 mg ORAL ANDA 16 sections
Clorazepate Dipotassium HUMAN PRESCRIPTION DRUG LABEL 1 67046-906 TABLET 7.50 mg ORAL ANDA 20 sections
Clorazepate dipotassium HUMAN PRESCRIPTION DRUG LABEL 1 67046-907 TABLET 15 mg ORAL ANDA 16 sections
Clorazepate Dipotassium Human Prescription Drug Label 1 70954-157 TABLET 15 mg ORAL ANDA 21 sections
Clorazepate Dipotassium Human Prescription Drug Label 1 70954-158 TABLET 7.50 mg ORAL ANDA 21 sections
Clorazepate Dipotassium Human Prescription Drug Label 1 70954-159 TABLET 3.75 mg ORAL ANDA 21 sections